ERBB2 and breast cancer: In addition, the good prognosis of our patients in all subgroups is in contrast with a possible PI3K-mTOR pathways’ activation, which are known to be related to endocrine resistance in luminal BC and a worse outcome in HER2 and TNBC [20,40,41,42,43,44].